Lead sponsor
University of Chicago
5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
5
Trials led
2
Active
266
Total enrollment
2
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Early Phase 1
1
Phase 2
1
Phase 3
1
Not applicable
2
Trials by status
Not yet recruiting
1
Recruiting
1
Completed
2
Suspended
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory IssuesBMI ≥27Early Ph 1Suspended30